When metastatic transitional cell cancer of the renal pelvis and ureter reaches advanced stages, treatment focuses on controlling symptoms, slowing disease progression, and maintaining the best possible quality of life for patients, rather than pursuing cure.

Understanding Treatment Goals When Cancer Has Spread

Transitional cell cancer that begins in the renal pelvis or ureter can sometimes spread beyond these structures to distant parts of the body. When this happens, the disease enters what doctors call the metastatic stage, meaning cancer cells have traveled through the bloodstream or lymphatic system to form new tumors in organs far from where the cancer originally started. The most common places where this cancer spreads include the lungs, liver, and bones.^[8]

The unfortunate reality is that patients with tumors that have penetrated through the wall of the renal pelvis or ureter, or those with distant metastases, usually cannot be cured with available forms of treatment.^[9] This is a difficult truth that patients and families must understand when making treatment decisions. When cancer reaches this stage, the approach to care shifts dramatically. Instead of trying to eliminate every cancer cell, doctors focus on managing the disease as a chronic condition, controlling its growth, alleviating painful or troubling symptoms, and helping patients maintain their independence and comfort for as long as possible.

The depth of cancer infiltration into or through the wall that lines the urinary tract is the major factor that determines how patients will fare over time. Superficial tumors that stay within the lining are likely to be well-behaved and respond to treatment, while tumors that burrow deeply through the walls tend to be aggressive and poorly organized under the microscope.^[9] Once the cancer has broken through these natural barriers, it gains access to blood vessels and lymph channels that can carry cancer cells throughout the body.

Treatment decisions for metastatic or recurrent disease depend on several factors beyond just the cancer’s stage. Doctors must consider where the cancer has spread, how quickly it appears to be growing, what symptoms it is causing, the patient’s overall health and kidney function, and importantly, what the patient’s own goals and preferences are for their care. Some patients may choose aggressive treatment to extend life as much as possible, while others may prioritize comfort and time with loved ones over intensive therapies that can cause side effects.

Standard Treatment Approaches for Advanced Disease

When transitional cell cancer of the renal pelvis or ureter has metastasized or recurred after initial treatment, surgery alone is no longer sufficient. Medical therapy becomes the cornerstone of treatment, with chemotherapy being the most established approach. Because these upper tract cancers arise from the same type of cells that line the bladder, doctors treat them similarly to bladder cancers rather than the more common type of kidney cancer called renal cell cancer.^[2]

Chemotherapy uses powerful drugs that travel through the bloodstream to reach cancer cells throughout the body. These medications work by interfering with the cancer cells’ ability to grow and divide. For metastatic transitional cell cancer, doctors typically use combinations of chemotherapy drugs rather than single agents, as combinations tend to be more effective at controlling the disease.

The standard chemotherapy regimen for advanced urothelial cancer traditionally includes a platinum-based drug called cisplatin, which is often combined with other chemotherapy agents. Cisplatin has been the backbone of treatment for decades because it has shown the most consistent activity against these cancers. However, cisplatin can only be used in patients whose kidneys are functioning reasonably well, as the drug can be toxic to kidney tissue. This presents a particular challenge for patients with upper tract cancer who may have already had a kidney removed during initial surgery or whose remaining kidney function has been compromised by the cancer itself.^[12]

For patients whose kidney function is too poor to tolerate cisplatin, or who have other medical conditions that make cisplatin unsuitable, doctors may use alternative chemotherapy combinations. These regimens may include drugs such as carboplatin, which is similar to cisplatin but gentler on the kidneys, combined with other anticancer agents. While these alternative regimens may not be quite as effective as cisplatin-based treatment, they still offer meaningful disease control for many patients.

The duration of chemotherapy treatment varies considerably depending on how well the cancer responds and how well the patient tolerates the treatment. Doctors typically administer chemotherapy in cycles, with periods of treatment followed by rest periods to allow the body to recover. Imaging scans are performed periodically to assess whether the cancer is shrinking, staying stable, or continuing to grow despite treatment. If the cancer responds well, chemotherapy may continue for several months. If the disease stops responding or if side effects become too severe, doctors may need to switch to a different treatment approach.

Chemotherapy can cause a range of side effects that vary depending on which drugs are used. Common side effects include fatigue, nausea and vomiting, loss of appetite, hair loss, increased risk of infections due to low white blood cell counts, anemia causing weakness and shortness of breath, and increased bleeding risk from low platelet counts. Cisplatin specifically can damage the kidneys and nerves, causing numbness and tingling in the hands and feet. Modern supportive care medications have significantly improved doctors’ ability to prevent or manage many of these side effects, making chemotherapy more tolerable than it was in the past.

In some cases, doctors may recommend radiation therapy as part of treatment for metastatic disease, particularly when cancer has spread to the bones causing pain, or to specific areas where tumor growth is causing problems such as bleeding or blockage. Radiation therapy uses high-energy beams to kill cancer cells in targeted areas. While radiation is not typically used as the main treatment for widely metastatic disease, it can be very helpful for palliative care—treatment aimed at relieving symptoms rather than curing the cancer. The role of radiation therapy in the overall management of upper urinary tract transitional cell cancer is not as well-defined as it is for some other cancers, but some studies suggest that adding radiation after surgery for high-grade disease may improve local control of the cancer.^[12]

Emerging Treatments Being Studied in Clinical Trials

Over the past decade, the landscape of treatment options for metastatic transitional cell cancer has expanded dramatically thanks to advances in cancer research. Scientists have developed new types of therapies that work through different mechanisms than traditional chemotherapy, and many of these are being tested in clinical trials or have recently been approved for use. These newer treatments offer hope, especially for patients whose cancer has stopped responding to chemotherapy or who cannot tolerate standard treatments.

One of the most significant advances has been the development of immunotherapy drugs, which harness the power of a patient’s own immune system to fight cancer. The immune system normally protects the body by identifying and destroying abnormal cells, including cancer cells. However, cancer cells often develop ways to hide from or suppress the immune system. Immunotherapy drugs work by blocking these cancer defense mechanisms, allowing the immune system to recognize and attack the cancer more effectively.

The most widely studied type of immunotherapy for metastatic urothelial cancer targets proteins called PD-1 and PD-L1. These proteins normally act as brakes on the immune system to prevent it from attacking healthy tissues. Cancer cells can exploit this system by displaying PD-L1 on their surface, essentially telling immune cells to leave them alone. Drugs that block PD-1 or PD-L1 release these brakes, reactivating immune cells called T-cells and enabling them to attack cancer cells. Several PD-1/PD-L1 inhibitor drugs have been studied in clinical trials for advanced transitional cell cancer and some have been approved for clinical use based on positive results showing they can shrink tumors and extend survival in some patients.^[12]

These immunotherapy drugs offer some important advantages over chemotherapy. They tend to cause different types of side effects that some patients find easier to tolerate than chemotherapy side effects. When immunotherapy does work, the benefits can sometimes last longer than those seen with chemotherapy, because the immune system can develop a memory that continues to recognize and fight cancer cells even after treatment stops. However, immunotherapy does not work for everyone—only a subset of patients responds to these treatments, and researchers are still working to identify which patients are most likely to benefit.

Another promising area of research involves targeted therapies that attack specific molecular abnormalities found in cancer cells. Scientists have discovered that some transitional cell cancers have mutations or changes in certain genes that drive cancer growth. By understanding these molecular changes, researchers have developed drugs designed to specifically block these abnormal pathways while sparing normal cells.

One particularly important target is a protein called FGFR (fibroblast growth factor receptor). Some patients with urothelial cancer have genetic alterations in FGFR genes that cause cancer cells to receive constant growth signals. FGFR inhibitor drugs can block these signals, causing cancer cells to stop growing or die. Clinical trials have tested several FGFR inhibitors in patients with advanced urothelial cancer who have specific FGFR genetic alterations, showing promising results in some cases.^[12] These drugs represent a form of precision medicine, where treatment is selected based on the specific molecular characteristics of a patient’s individual cancer.

Scientists are also investigating antibody-drug conjugates, which represent a clever combination approach to cancer treatment. These drugs consist of an antibody attached to a chemotherapy molecule. The antibody is designed to recognize and bind to specific proteins found on cancer cells. Once the antibody-drug conjugate attaches to a cancer cell, the cell takes it inside, where the chemotherapy is released to kill the cell from within. This approach allows chemotherapy to be delivered directly to cancer cells while minimizing exposure to healthy tissues, potentially improving effectiveness while reducing side effects. Several antibody-drug conjugates targeting different proteins on urothelial cancer cells have been tested in clinical trials, with some showing encouraging results.^[12]

Clinical trials testing these new approaches typically progress through three phases. Phase I trials focus primarily on safety, determining what dose of a new drug can be given safely and what side effects it causes. Phase II trials begin to assess whether the drug shows signs of effectiveness against cancer, usually measuring how many patients’ tumors shrink or stop growing. Phase III trials compare the new treatment directly against standard treatment in larger groups of patients to determine whether it offers better outcomes. Only treatments that prove safe and effective in clinical trials eventually become approved for routine use.

Patients with metastatic transitional cell cancer who are interested in accessing these newer therapies often need to enroll in clinical trials, as not all of these treatments are yet approved for standard use. Clinical trials are conducted at specialized cancer centers throughout the United States, Europe, and other parts of the world. Eligibility for specific trials depends on many factors, including the patient’s overall health, kidney function, what treatments they have already received, and specific characteristics of their cancer. Doctors can help patients explore whether there are appropriate clinical trials available for their situation.

An important consideration for all patients with metastatic cancer is that treatment is not always beneficial. As the disease progresses and patients undergo multiple lines of therapy, there comes a point for many when the burdens and side effects of continued cancer treatment outweigh any potential benefits. At this stage, transitioning to purely palliative care focused on comfort and symptom management may be the most appropriate choice. These difficult decisions should be made through honest conversations between patients, families, and the medical team about goals of care and quality of life.

Most common treatment methods

• Chemotherapy
  • Cisplatin-based regimens are the standard for patients with adequate kidney function
  • Alternative regimens using carboplatin for patients who cannot tolerate cisplatin
  • Combination drug regimens generally more effective than single agents
  • Administered in cycles with rest periods between treatments
  • Common side effects include fatigue, nausea, hair loss, and increased infection risk
• Immunotherapy
  • PD-1 and PD-L1 inhibitor drugs that activate the immune system against cancer
  • Can provide longer-lasting responses than chemotherapy in responding patients
  • Different side effect profile compared to chemotherapy
  • Not effective for all patients; subset responds well
  • Used in clinical trials and approved for certain situations
• Targeted Therapy
  • FGFR inhibitors for cancers with specific genetic alterations
  • Precision medicine approach based on molecular characteristics of individual tumors
  • May be more effective with fewer side effects than traditional chemotherapy
  • Requires genetic testing of tumor to identify suitable targets
• Radiation Therapy
  • Used for symptom relief when cancer spreads to bones or causes local problems
  • May improve local control when added after surgery for high-grade disease
  • Not typically used as main treatment for widespread metastatic disease
  • Targets specific problem areas with high-energy beams
• Antibody-Drug Conjugates
  • Combine targeted antibody with attached chemotherapy molecule
  • Deliver chemotherapy directly to cancer cells while sparing healthy tissue
  • Being tested in clinical trials with promising early results
  • Target specific proteins found on urothelial cancer cells